Conjunctivitis Treatment Market By Drug Class (Antibiotics, Antiviral, Anti-allergic, Artificial Tears), By Disease Type (Allergic Conjunctivitis, Bacterial Conjunctivitis, Viral Conjunctivitis), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global conjunctivitis treatment market was valued at $4,213.01 million in 2021, and is projected to reach $6,117.28 million by 2031, registering a CAGR of 3.8% from 2022 to 2031.
Conjunctivitis refers to the inflammation or infection of the conjunctiva. It is the most common presentation of eye redness in both primary care and the emergency department, therefore putting a large strain on the healthcare system. Conjunctivitis is a common cause of eye redness and subsequently a common complaint in the emergency department, urgent care, and primary care clinics. It can affect people of any age, demographic or socioeconomic status. Although usually self-limiting and rarely resulting in vision loss, when assessing for conjunctivitis, it is essential to rule out other sight-threatening causes of red-eye. The conjunctiva is the transparent, lubricating mucous membrane covering the outer surface of the eye. It is composed of two parts, the “bulbar conjunctiva” which covers the globe and the “tarsal conjunctiva” which lines the eyelid's inner surface. Conjunctivitis refers to the inflammation or infection of the conjunctiva. It can be acute or chronic and infectious or non-infectious. Acute conjunctivitis refers to symptom duration 3 to 4 weeks from presentation (usually only lasting 1 to 2 weeks) whereas chronic is defined as lasting more than 4 weeks.
Increase in access to diagnostic tests for conjunctivitis, rise in R&D activities by the market players, surge in strategic collaborations among the market players, and increase in product launches and approvals are expected to drive the growth of the global conjunctivitis treatment market. In addition, focus of governments on awareness programs, and rise in healthcare expenditure and pollution propel the growth of the conjunctivitis treatment market. Further, different technologies employed in the development of effective treatment boost the market growth.
However, high monetary inputs associated with manufacturing of the products restrict the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market during the forecast period.
The conjunctivitis treatment market is segmented on the basis of disease type, drug class, distribution channel, and region. By disease type, it is categorized into allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis. By drug class, it is classified into antibiotics, antiviral, anti-allergic, and artificial tears. By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
By disease type, the allergic conjunctivitis segment generated the highest revenue in the conjunctivitis treatment market in 2021 owing to increase in prevalence of allergic conjunctivitis. By drug class, the anti-allergic segment generated the highest revenue in the conjunctivitis treatment market in 2021, owing to advancements in anti-allergic drugs and new product launch. By distribution channel, the hospital pharmacy segment generated the highest revenue in the conjunctivitis treatment market in 2021, owing to increase in number of hospital pharmacy.
By region, North America accounted for the largest market share in the conjunctivitis treatment market in 2021 and is expected to retain its dominance throughout the forecast period. This is primarily attributed to increase in prevalence of conjunctivitis, presence of well-established healthcare infrastructure and rise in healthcare expenditure.
Asia-Pacific witnessed the highest growth rate for the conjunctivitis treatment market and is expected to continue this trend throughout the forecast period, which is attributed to presence of high population base and increase in healthcare expenditure.
The report provides a comprehensive analysis of the key players that operate in the global conjunctivitis treatment market. The key companies profiled in the report include AbbVie Inc., Ajanta Pharma Limited, AFT pharmaceuticals, Alembic Pharmaceuticals Ltd, Bausch Health Companies Inc , Cipla, Inc., Grevis Pharmaceutical Private Limited , Indoco Remedies Ltd., Jabs Biotech Pvt. Ltd., JAWA Pharmaceuticals Pvt. Ltd, Johnson & Johnson Services Inc., , Novartis AG, , Ocular Therapeutics, Inc., Santen Pharmaceuticals Co. Ltd., Spectra Vision Care Pvt. Ltd, Sun Pharmaceuticals Industries Ltd and Teva Pharmaceutical Industries Ltd.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the conjunctivitis treatment market analysis from 2021 to 2031 to identify the prevailing conjunctivitis treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the conjunctivitis treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global conjunctivitis treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Class
Antibiotics
Antiviral
Anti-allergic
Artificial Tears
By Disease Type
Allergic Conjunctivitis
Type
Seasonal Allergic Conjunctivitis
Perennial Allergic Conjunctivitis
Bacterial Conjunctivitis
Viral Conjunctivitis
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Abbvie Inc
Ajanta Pharma Limited
AFT Pharmaceuticals
Alembic Pharmaceuticals Ltd
Bausch Health Companies Inc
Cipla, Inc.
Grevis Pharmaceutical Private Limited
Indoco Remedies Ltd.
Jabs Biotech Pvt. Ltd.
JAWA Pharmaceuticals Pvt. Ltd
Johnson & Johnson Services Inc
Novartis AG
Ocular Therapeutics, Inc
Santen Pharmaceuticals Co. Ltd.
Spectra Vision Care Pvt. Ltd
Sun Pharmaceuticals Industries Ltd
Teva Pharmaceutical Industries Ltd
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook